E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with early stage (stage I-III) dMMR colon cancer |
Patienter med stadium I-III dMMR colon cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with colon cancer, that has not spread to other organs and are of the subtype dMMR (deficient mismatch repair). |
Patienter med colon cancer, der ikke har spredt sig til andre organer og er af typen dMMR. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10009951 |
E.1.2 | Term | Colon cancer NOS |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of this study is to evaluate the efficacy of neoadjuvant treatment with pembrolizumab before colonic resection in patients with early-stage (I-III) dMMR colon cancer. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives include investigating the safety and tolerability of pembrolizumab administered before surgery and developing predictive biomarkers that can identify patients with a pathological complete response to pembrolizumab. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Have histologically confirmed localized dMMR stage cT1N0M0 to cT4N2M0 (stage I to III) colon carcinoma. • Have indication for elective curative intended surgery without neoadjuvant chemo-therapy. • Be ≥ 18 years of age on the date of signing the informed consent. • Provide written informed consent prior to registration according to the local regula-tory requirements. • Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Have adequate bone marrow function: o Hemoglobin ≥ 6.2 mmol/L or ≥ 10 g/dL o Absolute neutrophil count (ANC) ≥ 1.5 × 109/L o Platelet count ≥ 100 × 109/L Have adequate kidney function: o Glomerular filtration rate (GFR) ≥ 60 mL/min or creatinine ≤1.5 X upper lim-it of normal (ULN) Have adequate liver function: o Total bilirubin ≤ 1.5 × ULN o Alanine aminotransferase (ALT): 10–70 U/L for males and 10–45 U/L for fe-males or ≤ 2.5 × ULN o Alkaline phosphatase: 35–105 U/L or ≤ 2.5 × ULN
|
|
E.4 | Principal exclusion criteria |
• Has any serious or uncontrolled medical disorder that, in the opinion of the investi-gator or treating physician, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results. • Has an autoimmune disorder (except thyroiditis with replacement therapy and type I diabetes mellitus). • Has received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody or any other antibody/drug specifically targeting the T-cell co-stimulation or checkpoint pathways. • Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active chronic or acute Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA is detected). • Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoim-mune disease. • Has a history of allergy to study drug components or a history of severe hypersensi-tivity reaction to any monoclonal antibody
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Number of patients with pathological complete response. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Evaluation after surgery with resection of the tumor. |
|
E.5.2 | Secondary end point(s) |
• Safety and tolerability of pembrolizumab administered before surgery. Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab using the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The attribution to drug, time-of-onset, duration of the event, its resolution, and any concomitant medications administered will be recorded. AEs will be analyzed including but not limited to all AEs, SAEs, fatal AEs, and laboratory changes. • Postoperative surgical complications determined by Clavien-Dindo classification system. • Number of patients with major pathological response to treatment, corresponding to Mandard tumor regression grade 1 (complete response) or 2 (near complete response). • Number of patients with clinical complete response • Overall survival. Defined as the time from inclusion to death due to any cause. • Disease-free survival. Defined as the time from inclusion to recurrence or death due to any cause. • Response evaluation at the pre-operative MDT meeting • Biomarker assessment including the comparison of immunological markers across pre- and post-treatment biopsies and sequential blood samples using nCounter and GeoMx platforms (NanoString technologies, USA). • Methylated circulating cell-free DNA (cfDNA) specific for colon cancer analyzed across sequential blood samples using the TriMeth test.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Analyses on blood and tissue samples will be done in bulk, when the samples have been collected. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study according to primary endpoint (Number of patients with pathological complete response), as recommended by the GCP Unit |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |